Novo Nordisk launched Awiqli® in the United States as the first once-weekly basal insulin for adults with type 2 diabetes. This treatment provides a convenient alternative to daily injections to improve patient adherence.
The launch expands the company’s portfolio of innovative treatments and marks a key milestone for its diabetes franchise. Management expects the weekly insulin to address the daily injection burden and serve as a significant growth driver.